ADAMTS13 activity is decreased in a septic porcine model

Summary

During sepsis, the balance between abundantly secreted von Wille-brand factor (VWF) and the activity of its size regulating protease ADAMTS13 is assumed to be involved in coagulation abnormalities. We aimed to establish a porcine model with haemorrhagic shock with consecutive sepsis and hypothesised that a decreased ADAMTS13-activity as well as an altered VWF multimer pattern is associated with renal failure. Animals (n=21) were subjected to haemorrhagic shock. After volume replacement, intraperitoneal Escherichia coli sepsis was induced. Blood samples were drawn at baseline, after haemorrhage and sepsis induction. Directly postmortem we examined renal tissue by JONES-silver, CD61, VWF and fibrin staining for characterisation of thrombi. Renal failure was analysed by scoring PAS-stained sections for acute tubular damage. Glomerular microthrombi were observed in six of 21 septic animals. Porcine ADAMTS13 activity declined significantly during sepsis, accompanied by a drop-off in platelet count. At 12 hours after sepsis induction, ADAMTS13 activity was significantly diminished compared to sham controls, and an elevated acute tubular damage score was associated with an increased proportion of high-molecular-weight VWF multimers. Compared to baseline the proportion of high-molecular-weight VWF multimers increased significantly in septic animals. Similar to human sepsis, diminished ADAMTS13 activity was observed in a septic porcine model associated with a shift to rather thrombogenic VWF multimers and deposition of microthrombi. Therefore, this porcine model seems to be appropriate for performing functional and therapeutic studies in sepsis-associated ADAMTS13 deficiency.

Keywords

Platelets - von Willebrand factor - renal failure - sepsis - thrombotic micro-angiopathy - multiple organ failure - histology

^* Both senior authors contributed equally.

• References

• 1 Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
• 2 Russell JA. Management of sepsis. N Engl J Med 2006; 355: 1699-1713.
• 3 Aird WC. The role of the endothelium in severe sepsis and multiple organ dys-function syndrome. Blood 2003; 101: 3765-3777.
• 4 Aird WC. Endothelium as a therapeutic target in sepsis. Curr Drug Targets 2007; 08: 501-507.
• 5 Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 01: 1335-1342.
• 6 Dong JF, Moake JL, Nolasco L. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
• 7 Nguyen TC, Han YY, Kiss JE. et al. Intensive plasma exchange increases ADAMTS-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med 2008; 36: 2878-2887.
• 8 Kremer Hovinga JA, Zeerleder S, Kessler P. et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007; 05: 2284-2290.
• 9 Bockmeyer CL, Claus RA, Budde U. et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008; 93: 137-140.
• 10 Ono T, Mimuro J, Madoiwa S. et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534.
• 11 Motto DG, Chauhan AK, Zhu G. et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-2761.
• 12 Chauhan AK, Walsh MT, Zhu G. et al. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008; 111: 3452-3451.
• 13 Kokame K, Nobe Y, Kokubo Y. et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
• 14 Mahdian R, Rayes J, Girma JP. et al. Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples. Thromb Haemost 2006; 95: 1049-1051.
• 15 Matejovic M, Krouzecky A, Radej J. et al. Coagulation and endothelial dysfunction during longterm hyperdynamic porcine bacteremia--effects of selective inducible nitric oxide synthase inhibition. Thromb Haemost 2007; 97: 304-309.
• 16 Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis 2006; 17: 445-451.
• 17 Buk SJ. Simultaneous demonstration of connective tissue elastica and fibrin by a combined Verhoeff ‘s elastic-Martius-scarlet-blue trichrome stain. Stain Technol 1984; 59: 1-5.
• 18 Martin K, Borgel D, Lerolle N. et al. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35: 2375-2382.
• 19 Claus RA, Bockmeyer CL, Budde U. et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-247.
• 20 Reiter RA, Varadi K, Turecek PL. et al. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005; 93: 554-558.
• 21 Mimuro J, Niimura M, Kashiwakura Y. et al. Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxinemia. Thromb Res 2008; 122: 91-97.
• 22 Chaudry IH, Ayala A. Mechanism of increased susceptibility to infection following hemorrhage. Am J Surg 1993; 165 2A 59S-67S.
• 23 Lustenberger T, Turina M, Seifert B. et al. The Severity of Injury and the Extent of Hemorrhagic Shock Predict the Incidence of Infectious Complications in Trauma Patients. Eur J Trauma Emerg Surg 2009; 35: 538-546.
• 24 Goldfarb RD, Dellinger RP, Parrillo JE. Porcine models of severe sepsis: emphasis on porcine peritonitis. Shock 2005; 24 (Suppl. 01) 75-81.
• 25 Castellheim A, Thorgersen EB, Hellerud BC. et al. New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs. Scand J Immunol 2008; 68: 75-84.
• 26 Schiff DE, Wass CA, Cryz Jr. SJ. et al. Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection. Infect Immun 1993; 61: 975-980.
• 27 Esmon CT. Why do animal models (sometimes) fail to mimic human sepsis?. Crit Care Med 2004; 32 (Suppl. 05) S219-222.
• 28 Matejovic M, Krouzecky A, Rokyta Jr. R. et al. Fluid challenge in patients at risk for fluid loading-induced pulmonary edema. Acta Anaesthesiol Scand 2004; 48: 69-73.
• 29 Gebhard F, Riepl C, Liener UC. et al. Volume replacement in trauma patients within the first 24 h and its impact on the interpretation of biochemical data. Langenbecks Arch Surg 2000; 385: 406-411.
• 30 Claus RA, Bockmeyer CL, Sossdorf M. et al. The Balance between von-Willebrand Factor and its Cleaving Protease ADAMTS13: Biomarker in Systemic Inflammation and Development of Organ Failure?. Curr Mol Med 10: 236-248.
• 31 Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60: 831-846.
• 32 Gunzer F, Hennig-Pauka I, Waldmann KH. et al. Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli. Am J Clin Pathol 2002; 118: 364-375.
• 33 Lerolle N, Dunois-Larde C, Badirou I. et al. Von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture. J Thromb Haemost 2009; 07: 843-850.
• 34 Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006; 57: 419-436.
• 35 Tsai HM. ADAMTS13 and microvascular thrombosis. Expert Rev Cardiovasc Ther 2006; 04: 813-825.
• 36 Rieger M, Ferrari S, Kremer Hovinga JA. et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost 2006; 95: 212-220.
• 37 Reiter RA, Knobl P, Varadi K. et al. Changes in von Willebrand factor-cleaving pro-tease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101: 946-948.
• 38 Bernardo A, Ball C, Nolasco L. et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-106.
• 39 Crawley JT, Lam JK, Rance JB. et al. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105: 1085-1093.
• 40 Manea M, Tati R, Karlsson J. et al. Biologically active ADAMTS13 is expressed in renal tubular epithelial cells. Pediatr Nephrol 2009; 25: 87-96.
• 41 Diener JL, Daniel Lagasse HA, Duerschmied D. et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 2009; 07: 1155-1162.